{"gene":"CIITA","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1994,"finding":"CIITA expression is controlled and induced by IFN-γ, and transfection of CIITA is sufficient to activate MHC class II gene expression in class II-negative cells in the absence of IFN-γ, establishing CIITA as the general regulator of both inducible and constitutive MHC class II expression.","method":"Transfection rescue experiments in class II-negative cells; IFN-γ stimulation assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1/2 — foundational gain-of-function rescue experiment, highly cited, replicated across many subsequent studies","pmids":["8016643"],"is_preprint":false},{"year":1997,"finding":"The CIITA gene is controlled by multiple distinct promoters: one directing constitutive expression in dendritic cells, one in B lymphocytes, and a third mediating IFN-γ-induced expression, explaining the cellular and functional diversity of MHC-II expression.","method":"Promoter-reporter transfection assays; cell-type-specific expression analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — multiple promoter-reporter constructs in distinct cell types, replicated broadly","pmids":["9184229"],"is_preprint":false},{"year":1995,"finding":"CIITA functions as a coactivator that directs its transcriptional activity through the X box element of MHC class II promoters; CIITA leads to formation of a higher-order complex at the X box region and contains a potent activation domain but does not bind DNA directly.","method":"DNA-mediated transfection with wild-type and mutant CIITA; gel-shift/complex formation assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — transfection rescue with promoter mutants and complex formation data, highly cited","pmids":["7749984"],"is_preprint":false},{"year":1997,"finding":"CIITA directly interacts with RFX5, a DNA-binding protein of the MHC class II regulatory complex, as demonstrated by yeast two-hybrid and far-Western assays; RFX5 determines promoter specificity via its DNA-binding domain while CIITA recruits the general transcription apparatus via its acidic activation domain.","method":"Yeast two-hybrid assay; far-Western blot; GAL4 fusion cotransfection in B cells and HeLa cells; complementation of CIITA-deficient RJ2.2.5 cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1/2 — two independent protein interaction assays plus functional complementation","pmids":["9177217"],"is_preprint":false},{"year":1997,"finding":"CIITA transactivates MHC class I gene expression through the site alpha DNA element; IFN-γ-induced MHC class I expression requires intact site alpha, and cells defective in CIITA induction (G3A) fail to induce MHC class I.","method":"Transfection of class I-deficient cell lines with CIITA; promoter mutant reporter assays; dominant-negative CIITA experiments; IFN-γ induction in G3A cells","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — two independent papers (PMID 9175837, 9175838) using complementary approaches showing the same finding","pmids":["9175837","9175838"],"is_preprint":false},{"year":2000,"finding":"CIITA binds to P-TEFb (Cyclin T1/CDK9 complex) through the same surface on Cyclin T1 used by HIV Tat; a dominant-negative CDK9 inhibits MHC II promoter activity, and CIITA activates transcription when tethered to RNA, establishing CIITA as a cellular coactivator that uses P-TEFb for target gene expression.","method":"Competition binding assays; dominant-negative CDK9 reporter assays; RNA-tethered transcription assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (competition, dominant-negative, RNA-tethering) in one study","pmids":["10661406"],"is_preprint":false},{"year":2000,"finding":"CIITA is acetylated at lysine residues within its nuclear localization signal by PCAF and CBP; acetylation regulates CIITA nuclear accumulation (shuttling between nucleus and cytoplasm), and mutagenesis of acetylated lysines reduces transactivation ability.","method":"Co-IP of CIITA with PCAF/CBP in vivo and in vitro; acetylation assays; trichostatin A treatment; mutagenesis of acetylated residues; nuclear/cytoplasmic fractionation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro acetylation assays combined with mutagenesis and cellular fractionation","pmids":["11046145"],"is_preprint":false},{"year":2000,"finding":"The leucine-rich repeat (LRR) region of CIITA is required for nuclear localization, in vivo recruitment to MHC class II promoters, and transactivation; LRR mutations abolish CIITA-RFX5 binding at the promoter (by ChIP) but not direct protein-protein interaction with RFX5 in pull-down, suggesting LRRs primarily govern nuclear import with an additional direct role in transcription.","method":"LRR alanine mutagenesis; chromatin immunoprecipitation (ChIP); nuclear localization microscopy; co-immunoprecipitation/pull-down with RFX5, RFXANK, NF-YB, NF-YC","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus mutagenesis plus multiple protein interaction assays in one study","pmids":["11003667"],"is_preprint":false},{"year":2001,"finding":"CIITA forms homo-oligomeric complexes with itself; the central GTP-binding domain is sufficient for self-association; LXXLL motifs in the GTP-binding domain are essential for self-association; and distinct regions mediate nuclear localization, activation function, and dominant-negative activity.","method":"Yeast two-hybrid; co-immunoprecipitation; domain-deletion analysis; subcellular localization assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2/3 — reciprocal co-IP and domain mapping in a single study","pmids":["11438649"],"is_preprint":false},{"year":2002,"finding":"BRG1, the ATPase subunit of the SWI/SNF chromatin-remodeling complex, is required for IFN-γ induction of CIITA; BRG1 interacts directly with the CIITA promoter in an IFN-γ-inducible manner (by ChIP), and an ATPase-dead BRG1 (K798R) fails to rescue CIITA induction, demonstrating that catalytic chromatin-remodeling activity is required.","method":"Chromatin immunoprecipitation; BRG1 reconstitution with wild-type vs. ATPase-dead mutant; DNase I footprinting; restriction enzyme accessibility assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1/2 — ATPase-dead mutant reconstitution combined with ChIP and chromatin accessibility assays","pmids":["11953317"],"is_preprint":false},{"year":2003,"finding":"CIITA ubiquitination enhances its association with MHC class II transcription factors and with the MHC class II promoter, resulting in increased transactivation; the degree of CIITA ubiquitination is controlled by histone acetyltransferases (HATs) and deacetylases (HDACs).","method":"Ubiquitination assays; co-immunoprecipitation; ChIP; HAT/HDAC inhibitor treatments","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ubiquitination assay, co-IP, ChIP) in a single study","pmids":["14528304"],"is_preprint":false},{"year":2003,"finding":"HDAC1 (in complex with mSin3A) physically associates with CIITA and suppresses CIITA-dependent MHC class II transcription by disrupting enhanceosome assembly (reducing NF-YB and RFX5 association with CIITA) and reducing H3 acetylation at MHC class II promoters.","method":"Co-immunoprecipitation of endogenous CIITA with HDAC1; GAL4-CIITA fusion reporter assay; ChIP for H3 acetylation and enhanceosome components; HDAC inhibitor (trichostatin A) treatment","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP plus ChIP plus functional reporter assays","pmids":["12697811"],"is_preprint":false},{"year":2003,"finding":"CIITA regulates transcription initiation at MHC class II genes by recruiting CDK7 and CDK9 kinases and enhancing CDK7-mediated phosphorylation of RNA Pol II at Ser5, leading to initiation of mRNA synthesis; CIITA is recruited to the enhanceosome, which subsequently recruits CBP and GCN5 coactivators and the SWI/SNF remodeling complex.","method":"Chromatin immunoprecipitation; temporal order analysis; kinase activity assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — ChIP-based temporal dissection combined with kinase activity measurements","pmids":["14517250"],"is_preprint":false},{"year":2004,"finding":"CIITA mediates IFN-γ-induced repression of collagen COL1A2 transcription; CIITA occupies the COL1A2 transcription start site in vivo (ChIP), is recruited there by RFX5, and displaces RNA polymerase II; shRNA knockdown of CIITA alleviates COL1A2 repression while also preventing MHC-II activation.","method":"ChIP; DNA affinity chromatography; shRNA knockdown; CIITA domain-deletion constructs with collagen promoter reporters","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — ChIP, affinity chromatography, and shRNA rescue with dual phenotypic readouts","pmids":["15247294"],"is_preprint":false},{"year":2004,"finding":"CIITA phosphorylation at serine residues 286, 288, and 293 in its nuclear-localized form down-regulates CIITA activity; mutations at these sites increase nuclear CIITA accumulation and enhance endogenous MHC class II expression from chromatin but not from plasmid-based promoters.","method":"Site-directed mutagenesis of serine residues; nuclear/cytoplasmic fractionation; endogenous MHC class II expression assays; promoter reporter assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis with both endogenous and reporter readouts; single lab","pmids":["15210796"],"is_preprint":false},{"year":2003,"finding":"Plexin-A1 is a novel transcriptional target of CIITA in dendritic cells; plexin-A1 knockdown by shRNA reduces T cell stimulation by antigen-pulsed DCs without affecting antigen processing or MHC peptide binding, defining a CIITA-dependent function in T cell–DC interaction.","method":"cDNA microarray of CIITA-deficient vs. control DCs; shRNA knockdown of plexin-A1; T cell stimulation assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — microarray identification followed by shRNA loss-of-function with functional T cell readout","pmids":["12910265"],"is_preprint":false},{"year":2011,"finding":"CIITA binds to myogenin and inhibits its activity in IFN-γ-treated myoblasts; CIITA is recruited to muscle-specific gene promoters coincident with reductions in RNA polymerase II recruitment, inhibiting myogenesis in both a gene-repression and protein-activity-inhibitory manner.","method":"Co-IP of CIITA with myogenin; ChIP at muscle-specific promoters; CIITA overexpression and shRNA knockdown; IFN-γ treatment of myoblasts and myotubes","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — co-IP combined with ChIP and bidirectional loss/gain-of-function with defined phenotype","pmids":["21576360"],"is_preprint":false},{"year":2011,"finding":"CIITA inhibits HTLV-1 replication by blocking the transactivating function of Tax-1; CIITA physically interacts with Tax-1 via CIITA residues 1–252 and 253–410 (and Tax-1 amino acids 1–108), and impairs Tax-1 association with coactivators PCAF, CREB, and ATF1 required for HTLV-1 LTR activation.","method":"Co-immunoprecipitation mapping of interaction domains; luciferase LTR reporter assay; overexpression rescue with PCAF/CREB/ATF1","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 — domain-level co-IP combined with functional reporter rescue experiments","pmids":["21813598"],"is_preprint":false},{"year":2016,"finding":"CIITA inhibits Tax-1-mediated NF-κB activation at both cytoplasmic and nuclear levels: in the cytoplasm, CIITA retains Tax-1 and maintains the inactive p50/RelA/IκB complex; in the nucleus, CIITA associates with Tax-1/RelA in nuclear bodies to block NF-κB-responsive gene activation; CIITA interacts with Tax-1 without preventing Tax-1 binding to IKKγ or RelA but affects Tax-1-induced IKK activity.","method":"Subcellular fractionation; co-immunoprecipitation; NF-κB reporter assays; IKK activity assays; nuclear body imaging with cytoplasmic/nuclear mutant CIITA forms","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with spatial dissection of mechanism","pmids":["26792751"],"is_preprint":false},{"year":2020,"finding":"CIITA induces resistance to Ebola virus and SARS-CoV-2 by activating expression of the CD74 p41 isoform, which inhibits viral entry by blocking cathepsin-mediated processing of the Ebola glycoprotein and the endosomal entry pathway of coronaviruses.","method":"Transposon-mediated gene-activation screen; CIITA/CD74 knockdown and overexpression; viral infection assays; mechanistic dissection with cathepsin inhibitors","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — genome-wide screen followed by mechanistic validation with loss/gain-of-function and pathway inhibitors","pmids":["32855215"],"is_preprint":false},{"year":2006,"finding":"Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-γ-induced CIITA expression through TLR2-dependent MAPK (p38/ERK) signaling that causes histone hypoacetylation at CIITA promoter IV and blocks recruitment of the BRG1 chromatin-remodeling protein to this promoter.","method":"Chromatin immunoprecipitation for histone acetylation; TLR2-/- macrophages; MAPK inhibitors (p38/ERK); BRG1 ChIP","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — ChIP combined with TLR2 KO and pharmacological inhibitors to dissect pathway","pmids":["16547269"],"is_preprint":false},{"year":2008,"finding":"BRG1 regulates CIITA induction through multiple interdependent distal enhancers rather than through the promoter alone; BRG1 is recruited to a far upstream site, triggering a histone activation mark that is prerequisite for subsequent IFN-γ-induced recruitment of STAT1, IRF1, and p300, and for chromatin looping.","method":"ChIP-seq; chromosome conformation capture (3C); deletion analysis of distal elements in BAC constructs","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — ChIP combined with 3C and BAC deletion functional assays","pmids":["18500344"],"is_preprint":false},{"year":2011,"finding":"SIRT1 deacetylates CIITA, protecting it from proteasomal degradation and promoting its nuclear accumulation and target promoter binding, thereby enhancing MHC class II transcription; stress stimuli (hypoxia, oxLDL) inhibit SIRT1 and increase CIITA acetylation, suppressing MHC II activation.","method":"Co-immunoprecipitation; deacetylation assays; proteasome inhibitor treatments; SIRT1 overexpression/silencing; ChIP; cellular fractionation","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — biochemical deacetylation assay combined with ChIP and multiple cellular readouts","pmids":["21890893"],"is_preprint":false},{"year":2017,"finding":"PRMT1 interacts with CIITA, methylates CIITA, and promotes CIITA degradation, thereby repressing MHC class II transcription; IFN-γ treatment down-regulates PRMT1 expression and attenuates its binding at the MHC II promoter.","method":"Co-immunoprecipitation; in vitro methylation assay; PRMT1 overexpression and knockdown; ChIP; CIITA stability assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical methylation assay plus ChIP and stability readouts; single lab","pmids":["28094290"],"is_preprint":false},{"year":2019,"finding":"CIITA recruits the histone H3K9 trimethyltransferase SUV39H1 to the eNOS promoter to repress eNOS transcription in endothelial cells; IFN-γ stimulation promotes CIITA occupancy on the eNOS promoter coincident with loss of H3K4Me3 and gain of H3K9Me3.","method":"ChIP assays for CIITA, SUV39H1, and histone marks; co-immunoprecipitation of CIITA with SUV39H1; CIITA overexpression/knockdown; SUV39H1 silencing","journal":"Biochimica et biophysica acta. Gene regulatory mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP combined with ChIP and bidirectional modulation; single lab","pmids":["30716531"],"is_preprint":false},{"year":2016,"finding":"PRMT5 interacts with CIITA and is recruited by CIITA to the MHC class II promoter; PRMT5 promotes H3R2 symmetric dimethylation at the MHC II promoter and synergizes with ASH2/WDR5 to activate MHC II transcription in an enzyme-activity-dependent manner.","method":"Co-immunoprecipitation; ChIP for PRMT5 and H3R2Me2s; PRMT5 overexpression and knockdown; enzyme-activity mutant","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP, ChIP, and enzyme-dead mutant in a single lab study","pmids":["26972221"],"is_preprint":false},{"year":2007,"finding":"EZH2, the histone H3K27 trimethyltransferase component of Polycomb repressive complex 2, is present at the CIITA promoter IV chromatin in uveal melanoma cells; high H3K27Me3 at this promoter correlates with reduced RNA Pol II recruitment and impaired IFN-γ-induced CIITA transcription; EZH2 knockdown restores CIITA induction.","method":"Chromatin immunoprecipitation for H3K27Me3 and EZH2; RNA Pol II ChIP; EZH2 siRNA knockdown","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP combined with RNAi rescue; single lab","pmids":["17911618"],"is_preprint":false},{"year":2023,"finding":"FBXO11, a member of the Skp1-Cullin-1-F-box E3 ligase complex, binds CIITA (identified by unbiased proteomics), ubiquitinates CIITA, and regulates CIITA protein half-life through the ubiquitin-proteasome system; FBXO11 deficiency increases MHC class II expression at the promoter, transcript, and surface levels.","method":"Unbiased proteomic identification of CIITA-binding proteins; co-immunoprecipitation; cycloheximide chase assay; FBXO11 knockout cells; MHC-II reporter and surface expression assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1/2 — unbiased proteomics plus biochemical E3 ligase assay plus KO cells with multiple readouts","pmids":["37279268"],"is_preprint":false},{"year":2018,"finding":"NFAT5 is required for CIITA and MHC class II expression specifically in macrophages (not dendritic cells); NFAT5 binds and activates a remote upstream enhancer of the Ciita locus that loops to interact with the myeloid Ciita promoter I, and this enhancer shows NFAT5-dependent H3K27 acetylation.","method":"NFAT5-deficient macrophages; ChIP-seq (NFAT5 immunoprecipitation); chromosome conformation capture; histone modification ChIP; in vivo graft rejection assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq, 3C, KO cells, and in vivo functional assay","pmids":["30327417"],"is_preprint":false},{"year":1998,"finding":"The RFX complex (including RFX5 and RFXAP) is required for both constitutive and CIITA-induced MHC class I, MHC class II, and beta2-microglobulin transactivation, and the X1 box within the S-X-Y region is the critical cis-element mediating CIITA-dependent transactivation of MHC class I and beta2m promoters.","method":"Type III BLS cell lines lacking RFX; promoter mutant reporter assays; complementation with RFX5 and RFXAP expression constructs","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic complementation in BLS patient cells combined with promoter mutant reporters","pmids":["9806639"],"is_preprint":false},{"year":2006,"finding":"CIITA in complex with RFX5 mediates IFN-γ-induced repression of collagen type I gene transcription in smooth muscle cells; IFN-γ increases nuclear levels of CIITA isoforms III and IV in SMCs correlating with decreased collagen type I and increased MHC II gene expression.","method":"CIITA isoform transfection; nuclear fractionation; COL1A promoter reporter assays; ChIP implied by previous work; RFX5 knockdown by simvastatin treatment","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2/3 — transfection and nuclear fractionation; mechanistic basis from prior studies; single lab","pmids":["16439692"],"is_preprint":false},{"year":2013,"finding":"CIITA possesses intrinsic acetyltransferase (AT) and kinase activities that contribute to MHC class I and II gene transcription; as a general transcription factor, CIITA functionally replaces the TFIID component TAF1, and its AT and kinase substrate specificities parallel those of TAF1.","method":"Review integrating enzymatic activity assays (acetyltransferase and kinase), mutagenesis data, and functional transcription assays from multiple studies","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 1/2 — summarizes enzymatic data from multiple studies but is a review; enzymatic activities established in primary data","pmids":["24391648"],"is_preprint":false},{"year":2014,"finding":"Genome-wide ChIP-seq mapping reveals 843 CIITA binding intervals covering 442 genes (95% outside the MHC), including histone gene clusters; 60% of intervals lack RFX5 binding, indicating CIITA can be recruited independently of the canonical enhanceosome at non-MHC loci; allele-specific NF-κB recruitment mediates trans-regulation by a CIITA intronic variant.","method":"ChIP-seq in primary human B cells and monocytes; eQTL mapping; allele-specific ChIP","journal":"Genome biology","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq with orthogonal eQTL and allele-specific validation","pmids":["25366989"],"is_preprint":false},{"year":2015,"finding":"Genome-wide CIITA ChIP-seq in Raji B cells identifies 480 binding sites predominantly at active promoters/enhancers; CIITA binding at non-regulated loci is associated with increased H3K27 acetylation, suggesting CIITA poises chromatin at these sites; computational modeling identifies XY-box sequence constraints that distinguish CIITA-regulated from merely CIITA-bound sites.","method":"ChIP-seq; CRISPR/Cas9-generated CIITA-null cells; RNA-seq in CIITA-null cells; computational sequence modeling","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq plus CRISPR KO with transcriptomic readout and computational validation","pmids":["25753668"],"is_preprint":false},{"year":2006,"finding":"CIITA negatively regulates IL-10 expression in dendritic cells; CIITA co-transfection with an IL-10 promoter reporter decreases IL-10 promoter activity, and reintroduction of CIITA into CIITA-/- DCs reduces IL-10 production, establishing a transcriptional repressor function of CIITA beyond MHC class II regulation.","method":"CIITA-/- mouse DCs; IL-10 promoter-reporter transfection; CIITA reconstitution; ELISA and RT-PCR","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — KO plus promoter reporter plus reconstitution; single lab","pmids":["15661876"],"is_preprint":false},{"year":2004,"finding":"CIITA, RFX, and CREB interact to form the MHC class II enhanceosome; RFX and CIITA make variable, promoter-dependent contributions to histone acetylation, TBP, TFIIB, and RNA Pol II recruitment across four co-regulated MHC class II family genes.","method":"ChIP for histones H3/H4 acetylation, TBP, TFIIB, Pol II in RFX-deficient and CIITA-deficient cells across multiple promoters","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — systematic ChIP across multiple genes in defined mutant cell lines","pmids":["11889043"],"is_preprint":false},{"year":2006,"finding":"CREB and phospho-CREB interact directly with both CIITA and the RFX5 subunit through the C-terminal domain of CREB; phosphorylation of CREB enhances MHC class II promoter transcription; phospho-CREB occupancy at the HLA-DRA promoter was detected by ChIP.","method":"Co-immunoprecipitation with CREB deletion mutants; reporter assays; ChIP","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2/3 — co-IP with domain mapping plus ChIP; single lab","pmids":["16730065"],"is_preprint":false}],"current_model":"CIITA is a non-DNA-binding NLR-family transcriptional coactivator that serves as the master regulator of MHC class II (and, secondarily, MHC class I) gene expression: it is expressed from cell-type-specific promoters induced by IFN-γ (via JAK-STAT1-IRF1 and BRG1/SWI/SNF-dependent chromatin remodeling), nucleates an enhanceosome by interacting with the DNA-binding factors RFX5/RFXANK, NF-Y, and CREB at conserved S-X-Y promoter modules, recruits P-TEFb (CDK9/Cyclin T1) and CDK7 to phosphorylate RNA Pol II Ser5 for transcription initiation, coordinates HAT (PCAF/CBP/GCN5) and HDAC activities to control histone acetylation, and is itself post-translationally regulated by acetylation (PCAF/SIRT1), phosphorylation (at Ser286/288/293), arginine methylation (PRMT1-mediated degradation), ubiquitination (enhancing function; FBXO11-mediated proteasomal degradation), and nuclear/cytoplasmic shuttling; beyond antigen presentation, CIITA acts as a viral restriction factor by competing with HIV Tat for P-TEFb and blocking HTLV-1 Tax-1-dependent NF-κB activation, and induces antiviral resistance by activating CD74 p41 to block cathepsin-mediated viral entry."},"narrative":{"teleology":[{"year":1994,"claim":"The identity of the factor controlling MHC class II induction was unknown; transfection of CIITA into class II-negative cells restored MHC-II expression without IFN-γ, establishing CIITA as the master regulator of both constitutive and inducible MHC class II transcription.","evidence":"Gain-of-function transfection rescue in class II-negative cells with IFN-γ stimulation assays","pmids":["8016643"],"confidence":"High","gaps":["Mechanism by which CIITA activates transcription without directly binding DNA was unknown","Whether CIITA controlled MHC class I was not addressed"]},{"year":1995,"claim":"How CIITA activates MHC-II promoters without DNA binding was unclear; domain analysis showed CIITA acts as a coactivator that directs activity through the X box element and nucleates a higher-order complex, possessing a potent activation domain but no DNA-binding capacity.","evidence":"Transfection with wild-type and mutant CIITA; gel-shift/complex formation assays at X box","pmids":["7749984"],"confidence":"High","gaps":["Identity of the DNA-binding partner(s) that tether CIITA to the promoter was not resolved","Activation domain targets were unknown"]},{"year":1997,"claim":"How CIITA is tethered to promoters and how its expression is diversified across cell types were open questions; RFX5 was identified as the direct DNA-binding partner providing promoter specificity, and three cell-type-specific promoters were mapped, explaining constitutive versus inducible expression patterns.","evidence":"Yeast two-hybrid and far-Western for RFX5 interaction; promoter-reporter assays in dendritic cells, B cells, and IFN-γ-treated cells","pmids":["9177217","9184229"],"confidence":"High","gaps":["Other enhanceosome components (NF-Y, CREB) had not yet been characterized as CIITA partners","How CIITA interfaces with the general transcription machinery was unknown"]},{"year":1997,"claim":"Whether CIITA regulated genes beyond MHC class II was untested; CIITA was shown to transactivate MHC class I genes through the site alpha element, broadening its role to the entire antigen presentation pathway.","evidence":"Transfection of CIITA into class I-deficient cells; promoter mutant reporters; IFN-γ induction in CIITA-induction-defective G3A cells","pmids":["9175837","9175838"],"confidence":"High","gaps":["Whether CIITA uses the same enhanceosome at class I versus class II promoters was unclear","RFX requirement for class I activation was not yet demonstrated"]},{"year":1998,"claim":"The requirement for the RFX complex at MHC class I and β2m promoters was uncertain; complementation of RFX-deficient BLS patient cells showed that RFX5/RFXAP and the X1 box are essential for CIITA-dependent transactivation of both MHC-I and MHC-II genes.","evidence":"Genetic complementation in type III BLS cells; promoter mutant reporters","pmids":["9806639"],"confidence":"High","gaps":["How the full enhanceosome assembles in ordered steps was not resolved","Whether additional cofactors beyond RFX are needed for class I activation was unclear"]},{"year":2000,"claim":"How CIITA connects to the transcription elongation/initiation machinery was unknown; CIITA was found to bind P-TEFb (Cyclin T1/CDK9) on the same surface used by HIV Tat, and CIITA was simultaneously shown to be acetylated by PCAF/CBP to regulate its nuclear-cytoplasmic shuttling.","evidence":"Competition binding assays and RNA-tethered transcription for P-TEFb; in vitro acetylation assays with mutagenesis and subcellular fractionation for acetylation","pmids":["10661406","11046145"],"confidence":"High","gaps":["Whether P-TEFb recruitment leads to Pol II CTD phosphorylation at CIITA target promoters was not shown","Kinases responsible for CIITA's own phosphorylation were unidentified"]},{"year":2000,"claim":"The contribution of the leucine-rich repeat (LRR) domain was undefined; LRR mutations abolished nuclear localization and in vivo promoter recruitment (by ChIP) without disrupting direct RFX5 binding, establishing the LRR as essential for nuclear import and chromatin-level function.","evidence":"LRR alanine mutagenesis; ChIP; nuclear localization microscopy; pull-down with enhanceosome components","pmids":["11003667"],"confidence":"High","gaps":["Whether LRRs sense a ligand analogous to other NLR proteins was not addressed","Structural basis of LRR-mediated nuclear import was not resolved"]},{"year":2001,"claim":"Whether CIITA functions as a monomer or oligomer was unknown; CIITA was shown to self-associate through its GTP-binding domain via LXXLL motifs, suggesting oligomerization is integral to its activity.","evidence":"Yeast two-hybrid; co-immunoprecipitation; domain-deletion analysis","pmids":["11438649"],"confidence":"Medium","gaps":["Stoichiometry of the oligomer was not determined","Whether GTP binding/hydrolysis regulates oligomerization was untested","Not independently confirmed by a second laboratory"]},{"year":2002,"claim":"How CIITA expression is epigenetically induced at its own locus was unclear; BRG1 was shown to be recruited to the CIITA promoter in an IFN-γ-dependent manner, and its ATPase activity was required for chromatin remodeling permitting CIITA transcription.","evidence":"ChIP for BRG1; reconstitution with ATPase-dead K798R mutant; DNase I footprinting and restriction enzyme accessibility","pmids":["11953317"],"confidence":"High","gaps":["Whether BRG1 acts directly or is recruited by a specific transcription factor at the CIITA locus was not defined","Distal regulatory elements had not been mapped"]},{"year":2003,"claim":"The temporal order of cofactor recruitment and the mechanism of transcription initiation at MHC-II promoters were unresolved; CIITA was shown to recruit CDK7 and CDK9, enhancing Ser5 phosphorylation of RNA Pol II to initiate transcription, while ubiquitination of CIITA enhanced enhanceosome association and HDAC1 antagonized it.","evidence":"ChIP-based temporal dissection; kinase activity assays; ubiquitination assays; co-IP of HDAC1/mSin3A with CIITA; HAT/HDAC inhibitor experiments","pmids":["14517250","14528304","12697811"],"confidence":"High","gaps":["The E3 ubiquitin ligase responsible for activating ubiquitination of CIITA was not identified","Whether CIITA ubiquitination is degradative or non-degradative in this context was ambiguous"]},{"year":2003,"claim":"Whether CIITA controlled non-MHC target genes was largely unexplored; microarray analysis of CIITA-deficient DCs identified plexin-A1 as a CIITA target whose knockdown impaired T cell stimulation, revealing CIITA's role in DC–T cell communication beyond antigen presentation.","evidence":"cDNA microarray in CIITA-deficient vs. control DCs; shRNA knockdown of plexin-A1; T cell stimulation assays","pmids":["12910265"],"confidence":"High","gaps":["Whether CIITA directly binds the plexin-A1 promoter was not shown","Breadth of non-MHC targets was not systematically assessed"]},{"year":2004,"claim":"Dual roles of CIITA as both activator and repressor at different loci were emerging; CIITA was found to repress collagen COL1A2 transcription by displacing RNA Pol II from the promoter via RFX5-mediated recruitment, while phosphorylation at Ser286/288/293 was shown to negatively regulate nuclear CIITA activity.","evidence":"ChIP and shRNA at COL1A2 promoter; site-directed mutagenesis of serine residues with endogenous MHC-II readout and nuclear fractionation","pmids":["15247294","15210796","11889043"],"confidence":"High","gaps":["Kinase(s) phosphorylating Ser286/288/293 were not identified","Whether collagen repression occurs in non-smooth-muscle cell contexts was untested"]},{"year":2006,"claim":"Pathogen evasion of CIITA and additional CIITA cofactors were being characterized; M. tuberculosis 19-kDa lipoprotein was found to silence CIITA via TLR2-MAPK-driven histone hypoacetylation at promoter IV, and CREB/phospho-CREB were shown to directly interact with CIITA and RFX5 to enhance enhanceosome function.","evidence":"ChIP in TLR2-/- macrophages with MAPK inhibitors; co-IP of CREB deletion mutants with CIITA; phospho-CREB ChIP","pmids":["16547269","16730065"],"confidence":"High","gaps":["Whether other pathogens use the same TLR2-MAPK-CIITA silencing axis was unknown","Structural basis of CREB–CIITA interaction was not resolved"]},{"year":2008,"claim":"How the CIITA locus is regulated at the three-dimensional chromatin level was unknown; BRG1 was found to be recruited to distal enhancers that loop to the CIITA promoter, establishing a hierarchical model in which BRG1-dependent histone activation marks precede STAT1/IRF1/p300 recruitment.","evidence":"ChIP-seq; chromosome conformation capture (3C); BAC deletion analysis of distal elements","pmids":["18500344"],"confidence":"High","gaps":["Whether additional transcription factors cooperate at the distal enhancer was not fully resolved","3D looping dynamics during IFN-γ signaling were not captured in real time"]},{"year":2011,"claim":"Post-translational control of CIITA stability and non-immune functions of CIITA were expanding; SIRT1 was identified as a CIITA deacetylase that stabilizes CIITA and promotes MHC-II expression, while CIITA was shown to inhibit myogenesis by binding myogenin and displacing Pol II from muscle gene promoters.","evidence":"Co-IP and deacetylation assays for SIRT1–CIITA; ChIP at muscle-specific promoters; CIITA overexpression/knockdown in myoblasts","pmids":["21890893","21576360"],"confidence":"High","gaps":["Whether SIRT1-CIITA axis operates in professional APCs in vivo was not tested","CIITA's role in muscle physiology under non-inflammatory conditions was not explored"]},{"year":2011,"claim":"Whether CIITA had direct antiviral functions beyond MHC upregulation was unknown; CIITA was found to physically interact with HTLV-1 Tax-1 and impair Tax-1 association with PCAF, CREB, and ATF1, thereby blocking HTLV-1 LTR activation.","evidence":"Domain-mapping co-IP; luciferase LTR reporter; coactivator overexpression rescue","pmids":["21813598"],"confidence":"High","gaps":["Whether this restriction operates in primary HTLV-1-infected T cells was not demonstrated","Mechanism by which CIITA displaces coactivators from Tax-1 was not structurally resolved"]},{"year":2014,"claim":"The genome-wide binding landscape of CIITA was unknown; ChIP-seq revealed ~800 CIITA binding intervals covering >400 genes, 95% outside the MHC, with 60% lacking RFX5, establishing that CIITA has widespread RFX-independent genomic occupancy and can poise chromatin via H3K27 acetylation.","evidence":"ChIP-seq in primary B cells and monocytes; CRISPR/Cas9 CIITA-null cells with RNA-seq; eQTL and allele-specific ChIP","pmids":["25366989","25753668"],"confidence":"High","gaps":["Functional significance of CIITA binding at most non-MHC sites was not determined","RFX-independent recruitment mechanism was not identified"]},{"year":2016,"claim":"How CIITA restricts HTLV-1-driven NF-κB signaling was mechanistically unresolved; CIITA was found to act at both cytoplasmic and nuclear levels—retaining Tax-1 in an inactive IκB complex in the cytoplasm and sequestering Tax-1/RelA in nuclear bodies—while PRMT5 was identified as a CIITA-recruited histone arginine methyltransferase that promotes MHC-II activation.","evidence":"Subcellular fractionation and nuclear body imaging for Tax-1/NF-κB; co-IP and ChIP with enzyme-dead PRMT5 mutant for MHC-II","pmids":["26792751","26972221"],"confidence":"High","gaps":["Whether CIITA-mediated NF-κB inhibition affects other NF-κB-dependent viral or cellular programs was not explored","Relative contribution of PRMT5 versus other histone modifiers at MHC-II promoters was not quantified"]},{"year":2018,"claim":"Macrophage-specific regulation of the CIITA locus was poorly understood; NFAT5 was found to bind and activate a remote upstream enhancer of Ciita that loops to macrophage-specific promoter I, with NFAT5-dependent H3K27 acetylation controlling macrophage MHC-II expression and graft rejection in vivo.","evidence":"NFAT5-deficient macrophages; ChIP-seq; 3C; in vivo graft rejection assay","pmids":["30417417"],"confidence":"High","gaps":["Whether NFAT5-CIITA axis is relevant in human macrophages was not shown","Signals activating NFAT5 at the CIITA enhancer were not defined"]},{"year":2020,"claim":"Whether CIITA could restrict viral entry independently of adaptive immunity was unknown; a genome-wide screen identified CIITA-driven expression of CD74 p41 as a mechanism blocking cathepsin-dependent processing required for Ebola virus and SARS-CoV-2 entry, establishing CIITA as an innate antiviral restriction factor.","evidence":"Transposon-mediated gene-activation screen; CIITA/CD74 knockdown and overexpression; viral infection assays with cathepsin inhibitors","pmids":["32855215"],"confidence":"High","gaps":["Whether CD74 p41-mediated restriction operates in primary macrophages or DCs during natural infection was not tested","Breadth of viruses susceptible to this mechanism was not determined"]},{"year":2023,"claim":"The E3 ligase controlling CIITA proteasomal turnover was unidentified; FBXO11 was discovered by unbiased proteomics as an SCF-type E3 ligase that ubiquitinates CIITA and determines its protein half-life, with FBXO11 deficiency increasing MHC-II expression at transcript, promoter, and surface levels.","evidence":"Unbiased proteomic identification; co-IP; cycloheximide chase; FBXO11 knockout cells; MHC-II reporter and surface expression","pmids":["37279268"],"confidence":"High","gaps":["Specific lysine residues on CIITA targeted by FBXO11 were not mapped","Whether FBXO11 and the previously described activating ubiquitination represent distinct ubiquitin chain types was not resolved"]},{"year":null,"claim":"Key unresolved questions include: the structural basis of enhanceosome assembly, whether GTP binding/hydrolysis by the NLR-type domain regulates CIITA activity, the functional impact of CIITA at the majority of its genome-wide binding sites outside the MHC, and the in vivo significance of CIITA's antiviral restriction functions during natural infection.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of CIITA or its enhanceosome exists","GTPase activity and potential ligand sensing by the NLR domain are functionally uncharacterized","Biological significance of RFX-independent genome-wide CIITA binding remains undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,3,4,5,12,13,35]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[17,18,19]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[31]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,7,14,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6,18]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,3,5,12,35]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,4,19,29]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[9,11,21,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[17,18,19,20]}],"complexes":["MHC-II enhanceosome (RFX5/RFXANK/NF-Y/CREB/CIITA)"],"partners":["RFX5","RFXANK","CDK9","CCNT1","PCAF","HDAC1","SIRT1","FBXO11"],"other_free_text":[]},"mechanistic_narrative":"CIITA is the master transcriptional coactivator of MHC class II genes and a key regulator of MHC class I expression, functioning as a non-DNA-binding NLR-family protein that nucleates an enhanceosome at conserved S-X-Y promoter modules by interacting with the DNA-binding factors RFX5, RFXANK, NF-Y, and CREB [PMID:7749984, PMID:9177217, PMID:11889043]. CIITA is expressed from cell-type-specific promoters whose induction by IFN-γ requires STAT1/IRF1 signaling and BRG1/SWI/SNF-dependent chromatin remodeling at distal enhancers, and it drives transcription initiation by recruiting P-TEFb (CDK9/Cyclin T1) and CDK7 to phosphorylate RNA Pol II Ser5, while coordinating histone acetyltransferases and deacetylases to control promoter acetylation state [PMID:8016643, PMID:11953317, PMID:18500344, PMID:10661406, PMID:14517250]. CIITA activity is regulated post-translationally by acetylation (PCAF/CBP; counteracted by SIRT1), phosphorylation at Ser286/288/293, arginine methylation by PRMT1 promoting degradation, and FBXO11-mediated ubiquitin-proteasomal turnover, all of which modulate its nuclear accumulation and enhanceosome occupancy [PMID:11046145, PMID:21890893, PMID:28094290, PMID:37279268]. Beyond antigen presentation, CIITA acts as a viral restriction factor—competing with HIV Tat for P-TEFb binding, blocking HTLV-1 Tax-1-dependent NF-κB activation, and inducing CD74 p41-dependent resistance to Ebola virus and SARS-CoV-2 entry—and represses non-immune genes including collagen and IL-10 [PMID:10661406, PMID:21813598, PMID:26792751, PMID:32855215, PMID:15247294]."},"prefetch_data":{"uniprot":{"accession":"P33076","full_name":"MHC class II transactivator","aliases":[],"length_aa":1130,"mass_kda":123.4,"function":"Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter (PubMed:16600381, PubMed:17493635, PubMed:7749984, PubMed:8402893, PubMed:40608405). Does not bind DNA (PubMed:16600381, PubMed:17493635, PubMed:7749984, PubMed:8402893). May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984, (PubMed:16600381, PubMed:17493635). Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter (PubMed:16600381, PubMed:17493635, PubMed:7749984, PubMed:8402893). Also mediates enhanced MHC class I transcription; the promoter element requirements for CIITA-mediated transcription are distinct from those of constitutive MHC class I transcription, and CIITA can functionally replace TAF1 at these genes. Activates CD74 transcription (PubMed:32855215). Exhibits intrinsic GTP-stimulated acetyltransferase activity (PubMed:11172716). Exhibits serine/threonine protein kinase activity: can phosphorylate the TFIID component TAF7, the RAP74 subunit of the general transcription factor TFIIF, histone H2B at 'Ser-37' and other histones (in vitro) (PubMed:24036077). Has antiviral activity against Ebola virus and coronaviruses, including SARS-CoV-2 (PubMed:32855215). Induces resistance by up-regulation of the p41 isoform of CD74, which blocks cathepsin-mediated cleavage of viral glycoproteins, thereby preventing viral fusion (PubMed:32855215) Exhibits dominant-negative suppression of MHC class II gene expression","subcellular_location":"Nucleus; Nucleus, PML body","url":"https://www.uniprot.org/uniprotkb/P33076/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CIITA","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CIITA","total_profiled":1310},"omim":[{"mim_id":"620815","title":"MHC CLASS II DEFICIENCY 2; MHC2D2","url":"https://www.omim.org/entry/620815"},{"mim_id":"615746","title":"ZXD FAMILY ZINC FINGER PROTEIN C; ZXDC","url":"https://www.omim.org/entry/615746"},{"mim_id":"615648","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 3; NLRC3","url":"https://www.omim.org/entry/615648"},{"mim_id":"613591","title":"BUTYROPHILIN, SUBFAMILY 2, MEMBER A2; BTN2A2","url":"https://www.omim.org/entry/613591"},{"mim_id":"613537","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 5; NLRC5","url":"https://www.omim.org/entry/613537"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":50.4}],"url":"https://www.proteinatlas.org/search/CIITA"},"hgnc":{"alias_symbol":["C2TA","NLRA"],"prev_symbol":["MHC2TA"]},"alphafold":{"accession":"P33076","domains":[{"cath_id":"3.40.50.300","chopping":"337-569","consensus_level":"high","plddt":74.4797,"start":337,"end":569},{"cath_id":"3.80.10.10","chopping":"916-1129","consensus_level":"medium","plddt":90.7375,"start":916,"end":1129},{"cath_id":"1.10.8","chopping":"572-634","consensus_level":"medium","plddt":89.3333,"start":572,"end":634}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P33076","model_url":"https://alphafold.ebi.ac.uk/files/AF-P33076-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P33076-F1-predicted_aligned_error_v6.png","plddt_mean":68.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CIITA","jax_strain_url":"https://www.jax.org/strain/search?query=CIITA"},"sequence":{"accession":"P33076","fasta_url":"https://rest.uniprot.org/uniprotkb/P33076.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P33076/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P33076"}},"corpus_meta":[{"pmid":"8016643","id":"PMC_8016643","title":"Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8016643","citation_count":757,"is_preprint":false},{"pmid":"21368758","id":"PMC_21368758","title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21368758","citation_count":471,"is_preprint":false},{"pmid":"9184229","id":"PMC_9184229","title":"Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9184229","citation_count":394,"is_preprint":false},{"pmid":"15162420","id":"PMC_15162420","title":"Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15162420","citation_count":232,"is_preprint":false},{"pmid":"10661406","id":"PMC_10661406","title":"Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10661406","citation_count":226,"is_preprint":false},{"pmid":"9175838","id":"PMC_9175838","title":"Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9175838","citation_count":177,"is_preprint":false},{"pmid":"9175837","id":"PMC_9175837","title":"Induction of MHC class I expression by the MHC class II transactivator CIITA.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9175837","citation_count":176,"is_preprint":false},{"pmid":"16547269","id":"PMC_16547269","title":"Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-gamma-induced chromatin remodeling of MHC2TA by TLR2 and MAPK signaling.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16547269","citation_count":171,"is_preprint":false},{"pmid":"7749984","id":"PMC_7749984","title":"Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA).","date":"1995","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7749984","citation_count":165,"is_preprint":false},{"pmid":"16870508","id":"PMC_16870508","title":"Epigenetic regulation of MHC-II and CIITA genes.","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16870508","citation_count":163,"is_preprint":false},{"pmid":"11046145","id":"PMC_11046145","title":"Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11046145","citation_count":133,"is_preprint":false},{"pmid":"12910265","id":"PMC_12910265","title":"CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions.","date":"2003","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12910265","citation_count":111,"is_preprint":false},{"pmid":"9177217","id":"PMC_9177217","title":"Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9177217","citation_count":111,"is_preprint":false},{"pmid":"9521055","id":"PMC_9521055","title":"Quantitative control of MHC class II expression by the transactivator CIITA.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9521055","citation_count":110,"is_preprint":false},{"pmid":"24391648","id":"PMC_24391648","title":"CIITA and Its Dual Roles in MHC Gene Transcription.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24391648","citation_count":98,"is_preprint":false},{"pmid":"32855215","id":"PMC_32855215","title":"MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32855215","citation_count":97,"is_preprint":false},{"pmid":"15467734","id":"PMC_15467734","title":"Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15467734","citation_count":96,"is_preprint":false},{"pmid":"18593762","id":"PMC_18593762","title":"Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18593762","citation_count":94,"is_preprint":false},{"pmid":"9806639","id":"PMC_9806639","title":"The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes.","date":"1998","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9806639","citation_count":91,"is_preprint":false},{"pmid":"11003667","id":"PMC_11003667","title":"CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11003667","citation_count":91,"is_preprint":false},{"pmid":"7495736","id":"PMC_7495736","title":"The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes.","date":"1995","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7495736","citation_count":90,"is_preprint":false},{"pmid":"11953317","id":"PMC_11953317","title":"Interferon-gamma-induced chromatin remodeling at the CIITA locus is BRG1 dependent.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11953317","citation_count":89,"is_preprint":false},{"pmid":"18500344","id":"PMC_18500344","title":"The chromatin-remodeling enzyme BRG1 coordinates CIITA induction through many interdependent distal enhancers.","date":"2008","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18500344","citation_count":88,"is_preprint":false},{"pmid":"16740768","id":"PMC_16740768","title":"CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16740768","citation_count":88,"is_preprint":false},{"pmid":"14528304","id":"PMC_14528304","title":"Enhancement of CIITA transcriptional function by ubiquitin.","date":"2003","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14528304","citation_count":87,"is_preprint":false},{"pmid":"31417570","id":"PMC_31417570","title":"CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31417570","citation_count":82,"is_preprint":false},{"pmid":"15653312","id":"PMC_15653312","title":"Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes.","date":"2005","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15653312","citation_count":82,"is_preprint":false},{"pmid":"12697811","id":"PMC_12697811","title":"Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12697811","citation_count":81,"is_preprint":false},{"pmid":"21464590","id":"PMC_21464590","title":"Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.","date":"2011","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21464590","citation_count":76,"is_preprint":false},{"pmid":"9885917","id":"PMC_9885917","title":"Mice lacking the transcription factor CIITA--a second look.","date":"1998","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9885917","citation_count":75,"is_preprint":false},{"pmid":"14517250","id":"PMC_14517250","title":"CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14517250","citation_count":72,"is_preprint":false},{"pmid":"21576360","id":"PMC_21576360","title":"Gamma interferon modulates myogenesis through the major histocompatibility complex class II transactivator, CIITA.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21576360","citation_count":68,"is_preprint":false},{"pmid":"33499042","id":"PMC_33499042","title":"The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33499042","citation_count":64,"is_preprint":false},{"pmid":"7495759","id":"PMC_7495759","title":"CIITA activates the expression of MHC class II genes in mouse T cells.","date":"1995","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7495759","citation_count":63,"is_preprint":false},{"pmid":"15240658","id":"PMC_15240658","title":"Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15240658","citation_count":63,"is_preprint":false},{"pmid":"16439692","id":"PMC_16439692","title":"Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.","date":"2006","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16439692","citation_count":56,"is_preprint":false},{"pmid":"17911618","id":"PMC_17911618","title":"A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17911618","citation_count":53,"is_preprint":false},{"pmid":"30327417","id":"PMC_30327417","title":"Macrophage-specific MHCII expression is regulated by a remote Ciita enhancer controlled by NFAT5.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30327417","citation_count":53,"is_preprint":false},{"pmid":"15528357","id":"PMC_15528357","title":"Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15528357","citation_count":51,"is_preprint":false},{"pmid":"15247294","id":"PMC_15247294","title":"Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma).","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15247294","citation_count":50,"is_preprint":false},{"pmid":"9144488","id":"PMC_9144488","title":"CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9144488","citation_count":49,"is_preprint":false},{"pmid":"11889043","id":"PMC_11889043","title":"Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11889043","citation_count":47,"is_preprint":false},{"pmid":"30716531","id":"PMC_30716531","title":"Class II transactivator (CIITA) mediates IFN-γ induced eNOS repression by enlisting SUV39H1.","date":"2019","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30716531","citation_count":45,"is_preprint":false},{"pmid":"15242870","id":"PMC_15242870","title":"E47, IRF-4, and PU.1 synergize to induce B-cell-specific activation of the class II transactivator promoter III (CIITA-PIII).","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15242870","citation_count":45,"is_preprint":false},{"pmid":"17012290","id":"PMC_17012290","title":"Role of the MHC2TA gene in autoimmune diseases.","date":"2006","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17012290","citation_count":43,"is_preprint":false},{"pmid":"15661876","id":"PMC_15661876","title":"Enhanced production of IL-10 by dendritic cells deficient in CIITA.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15661876","citation_count":43,"is_preprint":false},{"pmid":"12218128","id":"PMC_12218128","title":"Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12218128","citation_count":43,"is_preprint":false},{"pmid":"21653641","id":"PMC_21653641","title":"Interrogating the complex role of chromosome 16p13.13 in multiple sclerosis susceptibility: independent genetic signals in the CIITA-CLEC16A-SOCS1 gene complex.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21653641","citation_count":43,"is_preprint":false},{"pmid":"9894561","id":"PMC_9894561","title":"MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression.","date":"1998","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/9894561","citation_count":38,"is_preprint":false},{"pmid":"18601229","id":"PMC_18601229","title":"The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18601229","citation_count":38,"is_preprint":false},{"pmid":"26381931","id":"PMC_26381931","title":"Characterization of NLR-A subfamily members in miiuy croaker and comparative genomics revealed NLRX1 underwent duplication and lose in actinopterygii.","date":"2015","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26381931","citation_count":37,"is_preprint":false},{"pmid":"11438649","id":"PMC_11438649","title":"Self-association of CIITA and its transactivation potential.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11438649","citation_count":37,"is_preprint":false},{"pmid":"17300840","id":"PMC_17300840","title":"MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17300840","citation_count":37,"is_preprint":false},{"pmid":"32732833","id":"PMC_32732833","title":"Generation of GGTA1-/-β2M-/-CIITA-/- Pigs Using CRISPR/Cas9 Technology to Alleviate Xenogeneic Immune Reactions.","date":"2020","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/32732833","citation_count":36,"is_preprint":false},{"pmid":"26792751","id":"PMC_26792751","title":"The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-κB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein.","date":"2016","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/26792751","citation_count":36,"is_preprint":false},{"pmid":"25366989","id":"PMC_25366989","title":"Genomic mapping of the MHC transactivator CIITA using an integrated ChIP-seq and genetical genomics approach.","date":"2014","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/25366989","citation_count":35,"is_preprint":false},{"pmid":"18437201","id":"PMC_18437201","title":"Identification of CIITA regulated genetic module dedicated for antigen presentation.","date":"2008","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18437201","citation_count":34,"is_preprint":false},{"pmid":"19081173","id":"PMC_19081173","title":"Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19081173","citation_count":34,"is_preprint":false},{"pmid":"21813598","id":"PMC_21813598","title":"Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.","date":"2011","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/21813598","citation_count":34,"is_preprint":false},{"pmid":"12748124","id":"PMC_12748124","title":"Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.","date":"2003","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/12748124","citation_count":33,"is_preprint":false},{"pmid":"15950283","id":"PMC_15950283","title":"Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.","date":"2005","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15950283","citation_count":32,"is_preprint":false},{"pmid":"31969878","id":"PMC_31969878","title":"Helicobacter pylori Dampens HLA-II Expression on Macrophages via the Up-Regulation of miRNAs Targeting CIITA.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31969878","citation_count":32,"is_preprint":false},{"pmid":"11862382","id":"PMC_11862382","title":"Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.","date":"2002","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11862382","citation_count":31,"is_preprint":false},{"pmid":"24204280","id":"PMC_24204280","title":"IRF-4-mediated CIITA transcription is blocked by KSHV encoded LANA to inhibit MHC II presentation.","date":"2013","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/24204280","citation_count":31,"is_preprint":false},{"pmid":"21890893","id":"PMC_21890893","title":"SIRT1 links CIITA deacetylation to MHC II activation.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21890893","citation_count":30,"is_preprint":false},{"pmid":"16849401","id":"PMC_16849401","title":"MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16849401","citation_count":29,"is_preprint":false},{"pmid":"28094290","id":"PMC_28094290","title":"Protein arginine methyltransferase 1 (PRMT1) represses MHC II transcription in macrophages by methylating CIITA.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28094290","citation_count":29,"is_preprint":false},{"pmid":"17678724","id":"PMC_17678724","title":"Environment-gene interaction in multiple sclerosis: human herpesvirus 6 and MHC2TA.","date":"2007","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17678724","citation_count":28,"is_preprint":false},{"pmid":"25753668","id":"PMC_25753668","title":"Genome-wide CIITA-binding profile identifies sequence preferences that dictate function versus recruitment.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25753668","citation_count":28,"is_preprint":false},{"pmid":"20363966","id":"PMC_20363966","title":"PU.1 binds to a distal regulatory element that is necessary for B cell-specific expression of CIITA.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20363966","citation_count":28,"is_preprint":false},{"pmid":"21266852","id":"PMC_21266852","title":"Early epigenetic events regulate the adaptive immune response gene CIITA.","date":"2011","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/21266852","citation_count":28,"is_preprint":false},{"pmid":"16951349","id":"PMC_16951349","title":"Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16951349","citation_count":27,"is_preprint":false},{"pmid":"16879803","id":"PMC_16879803","title":"Epigenetic silencing of MHC2TA transcription in cancer.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16879803","citation_count":25,"is_preprint":false},{"pmid":"27089879","id":"PMC_27089879","title":"The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.","date":"2016","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27089879","citation_count":25,"is_preprint":false},{"pmid":"8666795","id":"PMC_8666795","title":"Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8666795","citation_count":25,"is_preprint":false},{"pmid":"15210796","id":"PMC_15210796","title":"Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15210796","citation_count":25,"is_preprint":false},{"pmid":"37467968","id":"PMC_37467968","title":"The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.","date":"2023","source":"Biomedical journal","url":"https://pubmed.ncbi.nlm.nih.gov/37467968","citation_count":24,"is_preprint":false},{"pmid":"17875550","id":"PMC_17875550","title":"The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association.","date":"2007","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17875550","citation_count":24,"is_preprint":false},{"pmid":"32188757","id":"PMC_32188757","title":"In Primitive Zebrafish, MHC Class II Expression Is Regulated by IFN-γ, IRF1, and Two Forms of CIITA.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32188757","citation_count":24,"is_preprint":false},{"pmid":"10845913","id":"PMC_10845913","title":"Synergistic induction of HLA class I expression by RelA and CIITA.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10845913","citation_count":23,"is_preprint":false},{"pmid":"28736195","id":"PMC_28736195","title":"Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28736195","citation_count":22,"is_preprint":false},{"pmid":"14768052","id":"PMC_14768052","title":"A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14768052","citation_count":22,"is_preprint":false},{"pmid":"15326139","id":"PMC_15326139","title":"Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.","date":"2004","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/15326139","citation_count":22,"is_preprint":false},{"pmid":"12565840","id":"PMC_12565840","title":"Human trophoblast noncoding RNA suppresses CIITA promoter III activity in murine B-lymphocytes.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12565840","citation_count":22,"is_preprint":false},{"pmid":"21614020","id":"PMC_21614020","title":"The rs4774 CIITA missense variant is associated with risk of systemic lupus erythematosus.","date":"2011","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21614020","citation_count":22,"is_preprint":false},{"pmid":"37279268","id":"PMC_37279268","title":"FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37279268","citation_count":21,"is_preprint":false},{"pmid":"25765819","id":"PMC_25765819","title":"A2b adenosine signaling represses CIITA transcription via an epigenetic mechanism in vascular smooth muscle cells.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25765819","citation_count":21,"is_preprint":false},{"pmid":"34303919","id":"PMC_34303919","title":"Induction of CIITA by IFN-γ in macrophages involves STAT1 activation by JAK and JNK.","date":"2021","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34303919","citation_count":21,"is_preprint":false},{"pmid":"23621273","id":"PMC_23621273","title":"Exosomes from CIITA-transfected CT26 cells enhance anti- tumor effects.","date":"2013","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23621273","citation_count":21,"is_preprint":false},{"pmid":"23052709","id":"PMC_23052709","title":"Age-dependent variation of genotypes in MHC II transactivator gene (CIITA) in controls and association to type 1 diabetes.","date":"2012","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23052709","citation_count":21,"is_preprint":false},{"pmid":"10329350","id":"PMC_10329350","title":"Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA.","date":"1999","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/10329350","citation_count":21,"is_preprint":false},{"pmid":"26972221","id":"PMC_26972221","title":"The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26972221","citation_count":20,"is_preprint":false},{"pmid":"16730065","id":"PMC_16730065","title":"CREB and phospho-CREB interact with RFX5 and CIITA to regulate MHC class II genes.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16730065","citation_count":20,"is_preprint":false},{"pmid":"17075826","id":"PMC_17075826","title":"Investigation of the MHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort.","date":"2006","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/17075826","citation_count":20,"is_preprint":false},{"pmid":"32173694","id":"PMC_32173694","title":"NLR-A Simple Indicator of Inflammation for the Diagnosis of Left Ventricular Hypertrophy in Patients with Hypertension.","date":"2020","source":"International heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/32173694","citation_count":20,"is_preprint":false},{"pmid":"16776848","id":"PMC_16776848","title":"The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients.","date":"2006","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16776848","citation_count":19,"is_preprint":false},{"pmid":"15351782","id":"PMC_15351782","title":"T cell expression of CIITA represses Th1 immunity.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15351782","citation_count":19,"is_preprint":false},{"pmid":"38168631","id":"PMC_38168631","title":"LncRNA-HOXC-AS2 regulates tumor-associated macrophage polarization through the STAT1/SOCS1 and STAT1/CIITA pathways to promote the progression of non-small cell lung cancer.","date":"2023","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/38168631","citation_count":19,"is_preprint":false},{"pmid":"15876426","id":"PMC_15876426","title":"Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus.","date":"2005","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15876426","citation_count":19,"is_preprint":false},{"pmid":"16235089","id":"PMC_16235089","title":"Lack of MHC-II expression in activated mouse T cells correlates with DNA methylation at the CIITA-PIII region.","date":"2005","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16235089","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47939,"output_tokens":8751,"usd":0.137541},"stage2":{"model":"claude-opus-4-6","input_tokens":12644,"output_tokens":5644,"usd":0.30648},"total_usd":0.444021,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"CIITA expression is controlled and induced by IFN-γ, and transfection of CIITA is sufficient to activate MHC class II gene expression in class II-negative cells in the absence of IFN-γ, establishing CIITA as the general regulator of both inducible and constitutive MHC class II expression.\",\n      \"method\": \"Transfection rescue experiments in class II-negative cells; IFN-γ stimulation assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — foundational gain-of-function rescue experiment, highly cited, replicated across many subsequent studies\",\n      \"pmids\": [\"8016643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The CIITA gene is controlled by multiple distinct promoters: one directing constitutive expression in dendritic cells, one in B lymphocytes, and a third mediating IFN-γ-induced expression, explaining the cellular and functional diversity of MHC-II expression.\",\n      \"method\": \"Promoter-reporter transfection assays; cell-type-specific expression analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple promoter-reporter constructs in distinct cell types, replicated broadly\",\n      \"pmids\": [\"9184229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CIITA functions as a coactivator that directs its transcriptional activity through the X box element of MHC class II promoters; CIITA leads to formation of a higher-order complex at the X box region and contains a potent activation domain but does not bind DNA directly.\",\n      \"method\": \"DNA-mediated transfection with wild-type and mutant CIITA; gel-shift/complex formation assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transfection rescue with promoter mutants and complex formation data, highly cited\",\n      \"pmids\": [\"7749984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CIITA directly interacts with RFX5, a DNA-binding protein of the MHC class II regulatory complex, as demonstrated by yeast two-hybrid and far-Western assays; RFX5 determines promoter specificity via its DNA-binding domain while CIITA recruits the general transcription apparatus via its acidic activation domain.\",\n      \"method\": \"Yeast two-hybrid assay; far-Western blot; GAL4 fusion cotransfection in B cells and HeLa cells; complementation of CIITA-deficient RJ2.2.5 cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — two independent protein interaction assays plus functional complementation\",\n      \"pmids\": [\"9177217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CIITA transactivates MHC class I gene expression through the site alpha DNA element; IFN-γ-induced MHC class I expression requires intact site alpha, and cells defective in CIITA induction (G3A) fail to induce MHC class I.\",\n      \"method\": \"Transfection of class I-deficient cell lines with CIITA; promoter mutant reporter assays; dominant-negative CIITA experiments; IFN-γ induction in G3A cells\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent papers (PMID 9175837, 9175838) using complementary approaches showing the same finding\",\n      \"pmids\": [\"9175837\", \"9175838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CIITA binds to P-TEFb (Cyclin T1/CDK9 complex) through the same surface on Cyclin T1 used by HIV Tat; a dominant-negative CDK9 inhibits MHC II promoter activity, and CIITA activates transcription when tethered to RNA, establishing CIITA as a cellular coactivator that uses P-TEFb for target gene expression.\",\n      \"method\": \"Competition binding assays; dominant-negative CDK9 reporter assays; RNA-tethered transcription assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (competition, dominant-negative, RNA-tethering) in one study\",\n      \"pmids\": [\"10661406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CIITA is acetylated at lysine residues within its nuclear localization signal by PCAF and CBP; acetylation regulates CIITA nuclear accumulation (shuttling between nucleus and cytoplasm), and mutagenesis of acetylated lysines reduces transactivation ability.\",\n      \"method\": \"Co-IP of CIITA with PCAF/CBP in vivo and in vitro; acetylation assays; trichostatin A treatment; mutagenesis of acetylated residues; nuclear/cytoplasmic fractionation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro acetylation assays combined with mutagenesis and cellular fractionation\",\n      \"pmids\": [\"11046145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The leucine-rich repeat (LRR) region of CIITA is required for nuclear localization, in vivo recruitment to MHC class II promoters, and transactivation; LRR mutations abolish CIITA-RFX5 binding at the promoter (by ChIP) but not direct protein-protein interaction with RFX5 in pull-down, suggesting LRRs primarily govern nuclear import with an additional direct role in transcription.\",\n      \"method\": \"LRR alanine mutagenesis; chromatin immunoprecipitation (ChIP); nuclear localization microscopy; co-immunoprecipitation/pull-down with RFX5, RFXANK, NF-YB, NF-YC\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus mutagenesis plus multiple protein interaction assays in one study\",\n      \"pmids\": [\"11003667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CIITA forms homo-oligomeric complexes with itself; the central GTP-binding domain is sufficient for self-association; LXXLL motifs in the GTP-binding domain are essential for self-association; and distinct regions mediate nuclear localization, activation function, and dominant-negative activity.\",\n      \"method\": \"Yeast two-hybrid; co-immunoprecipitation; domain-deletion analysis; subcellular localization assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — reciprocal co-IP and domain mapping in a single study\",\n      \"pmids\": [\"11438649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BRG1, the ATPase subunit of the SWI/SNF chromatin-remodeling complex, is required for IFN-γ induction of CIITA; BRG1 interacts directly with the CIITA promoter in an IFN-γ-inducible manner (by ChIP), and an ATPase-dead BRG1 (K798R) fails to rescue CIITA induction, demonstrating that catalytic chromatin-remodeling activity is required.\",\n      \"method\": \"Chromatin immunoprecipitation; BRG1 reconstitution with wild-type vs. ATPase-dead mutant; DNase I footprinting; restriction enzyme accessibility assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — ATPase-dead mutant reconstitution combined with ChIP and chromatin accessibility assays\",\n      \"pmids\": [\"11953317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CIITA ubiquitination enhances its association with MHC class II transcription factors and with the MHC class II promoter, resulting in increased transactivation; the degree of CIITA ubiquitination is controlled by histone acetyltransferases (HATs) and deacetylases (HDACs).\",\n      \"method\": \"Ubiquitination assays; co-immunoprecipitation; ChIP; HAT/HDAC inhibitor treatments\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ubiquitination assay, co-IP, ChIP) in a single study\",\n      \"pmids\": [\"14528304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HDAC1 (in complex with mSin3A) physically associates with CIITA and suppresses CIITA-dependent MHC class II transcription by disrupting enhanceosome assembly (reducing NF-YB and RFX5 association with CIITA) and reducing H3 acetylation at MHC class II promoters.\",\n      \"method\": \"Co-immunoprecipitation of endogenous CIITA with HDAC1; GAL4-CIITA fusion reporter assay; ChIP for H3 acetylation and enhanceosome components; HDAC inhibitor (trichostatin A) treatment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus ChIP plus functional reporter assays\",\n      \"pmids\": [\"12697811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CIITA regulates transcription initiation at MHC class II genes by recruiting CDK7 and CDK9 kinases and enhancing CDK7-mediated phosphorylation of RNA Pol II at Ser5, leading to initiation of mRNA synthesis; CIITA is recruited to the enhanceosome, which subsequently recruits CBP and GCN5 coactivators and the SWI/SNF remodeling complex.\",\n      \"method\": \"Chromatin immunoprecipitation; temporal order analysis; kinase activity assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-based temporal dissection combined with kinase activity measurements\",\n      \"pmids\": [\"14517250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CIITA mediates IFN-γ-induced repression of collagen COL1A2 transcription; CIITA occupies the COL1A2 transcription start site in vivo (ChIP), is recruited there by RFX5, and displaces RNA polymerase II; shRNA knockdown of CIITA alleviates COL1A2 repression while also preventing MHC-II activation.\",\n      \"method\": \"ChIP; DNA affinity chromatography; shRNA knockdown; CIITA domain-deletion constructs with collagen promoter reporters\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, affinity chromatography, and shRNA rescue with dual phenotypic readouts\",\n      \"pmids\": [\"15247294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CIITA phosphorylation at serine residues 286, 288, and 293 in its nuclear-localized form down-regulates CIITA activity; mutations at these sites increase nuclear CIITA accumulation and enhance endogenous MHC class II expression from chromatin but not from plasmid-based promoters.\",\n      \"method\": \"Site-directed mutagenesis of serine residues; nuclear/cytoplasmic fractionation; endogenous MHC class II expression assays; promoter reporter assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with both endogenous and reporter readouts; single lab\",\n      \"pmids\": [\"15210796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Plexin-A1 is a novel transcriptional target of CIITA in dendritic cells; plexin-A1 knockdown by shRNA reduces T cell stimulation by antigen-pulsed DCs without affecting antigen processing or MHC peptide binding, defining a CIITA-dependent function in T cell–DC interaction.\",\n      \"method\": \"cDNA microarray of CIITA-deficient vs. control DCs; shRNA knockdown of plexin-A1; T cell stimulation assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — microarray identification followed by shRNA loss-of-function with functional T cell readout\",\n      \"pmids\": [\"12910265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CIITA binds to myogenin and inhibits its activity in IFN-γ-treated myoblasts; CIITA is recruited to muscle-specific gene promoters coincident with reductions in RNA polymerase II recruitment, inhibiting myogenesis in both a gene-repression and protein-activity-inhibitory manner.\",\n      \"method\": \"Co-IP of CIITA with myogenin; ChIP at muscle-specific promoters; CIITA overexpression and shRNA knockdown; IFN-γ treatment of myoblasts and myotubes\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP combined with ChIP and bidirectional loss/gain-of-function with defined phenotype\",\n      \"pmids\": [\"21576360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CIITA inhibits HTLV-1 replication by blocking the transactivating function of Tax-1; CIITA physically interacts with Tax-1 via CIITA residues 1–252 and 253–410 (and Tax-1 amino acids 1–108), and impairs Tax-1 association with coactivators PCAF, CREB, and ATF1 required for HTLV-1 LTR activation.\",\n      \"method\": \"Co-immunoprecipitation mapping of interaction domains; luciferase LTR reporter assay; overexpression rescue with PCAF/CREB/ATF1\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain-level co-IP combined with functional reporter rescue experiments\",\n      \"pmids\": [\"21813598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CIITA inhibits Tax-1-mediated NF-κB activation at both cytoplasmic and nuclear levels: in the cytoplasm, CIITA retains Tax-1 and maintains the inactive p50/RelA/IκB complex; in the nucleus, CIITA associates with Tax-1/RelA in nuclear bodies to block NF-κB-responsive gene activation; CIITA interacts with Tax-1 without preventing Tax-1 binding to IKKγ or RelA but affects Tax-1-induced IKK activity.\",\n      \"method\": \"Subcellular fractionation; co-immunoprecipitation; NF-κB reporter assays; IKK activity assays; nuclear body imaging with cytoplasmic/nuclear mutant CIITA forms\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with spatial dissection of mechanism\",\n      \"pmids\": [\"26792751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CIITA induces resistance to Ebola virus and SARS-CoV-2 by activating expression of the CD74 p41 isoform, which inhibits viral entry by blocking cathepsin-mediated processing of the Ebola glycoprotein and the endosomal entry pathway of coronaviruses.\",\n      \"method\": \"Transposon-mediated gene-activation screen; CIITA/CD74 knockdown and overexpression; viral infection assays; mechanistic dissection with cathepsin inhibitors\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide screen followed by mechanistic validation with loss/gain-of-function and pathway inhibitors\",\n      \"pmids\": [\"32855215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-γ-induced CIITA expression through TLR2-dependent MAPK (p38/ERK) signaling that causes histone hypoacetylation at CIITA promoter IV and blocks recruitment of the BRG1 chromatin-remodeling protein to this promoter.\",\n      \"method\": \"Chromatin immunoprecipitation for histone acetylation; TLR2-/- macrophages; MAPK inhibitors (p38/ERK); BRG1 ChIP\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP combined with TLR2 KO and pharmacological inhibitors to dissect pathway\",\n      \"pmids\": [\"16547269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRG1 regulates CIITA induction through multiple interdependent distal enhancers rather than through the promoter alone; BRG1 is recruited to a far upstream site, triggering a histone activation mark that is prerequisite for subsequent IFN-γ-induced recruitment of STAT1, IRF1, and p300, and for chromatin looping.\",\n      \"method\": \"ChIP-seq; chromosome conformation capture (3C); deletion analysis of distal elements in BAC constructs\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP combined with 3C and BAC deletion functional assays\",\n      \"pmids\": [\"18500344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SIRT1 deacetylates CIITA, protecting it from proteasomal degradation and promoting its nuclear accumulation and target promoter binding, thereby enhancing MHC class II transcription; stress stimuli (hypoxia, oxLDL) inhibit SIRT1 and increase CIITA acetylation, suppressing MHC II activation.\",\n      \"method\": \"Co-immunoprecipitation; deacetylation assays; proteasome inhibitor treatments; SIRT1 overexpression/silencing; ChIP; cellular fractionation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — biochemical deacetylation assay combined with ChIP and multiple cellular readouts\",\n      \"pmids\": [\"21890893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRMT1 interacts with CIITA, methylates CIITA, and promotes CIITA degradation, thereby repressing MHC class II transcription; IFN-γ treatment down-regulates PRMT1 expression and attenuates its binding at the MHC II promoter.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; PRMT1 overexpression and knockdown; ChIP; CIITA stability assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical methylation assay plus ChIP and stability readouts; single lab\",\n      \"pmids\": [\"28094290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CIITA recruits the histone H3K9 trimethyltransferase SUV39H1 to the eNOS promoter to repress eNOS transcription in endothelial cells; IFN-γ stimulation promotes CIITA occupancy on the eNOS promoter coincident with loss of H3K4Me3 and gain of H3K9Me3.\",\n      \"method\": \"ChIP assays for CIITA, SUV39H1, and histone marks; co-immunoprecipitation of CIITA with SUV39H1; CIITA overexpression/knockdown; SUV39H1 silencing\",\n      \"journal\": \"Biochimica et biophysica acta. Gene regulatory mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP combined with ChIP and bidirectional modulation; single lab\",\n      \"pmids\": [\"30716531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PRMT5 interacts with CIITA and is recruited by CIITA to the MHC class II promoter; PRMT5 promotes H3R2 symmetric dimethylation at the MHC II promoter and synergizes with ASH2/WDR5 to activate MHC II transcription in an enzyme-activity-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation; ChIP for PRMT5 and H3R2Me2s; PRMT5 overexpression and knockdown; enzyme-activity mutant\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP, ChIP, and enzyme-dead mutant in a single lab study\",\n      \"pmids\": [\"26972221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"EZH2, the histone H3K27 trimethyltransferase component of Polycomb repressive complex 2, is present at the CIITA promoter IV chromatin in uveal melanoma cells; high H3K27Me3 at this promoter correlates with reduced RNA Pol II recruitment and impaired IFN-γ-induced CIITA transcription; EZH2 knockdown restores CIITA induction.\",\n      \"method\": \"Chromatin immunoprecipitation for H3K27Me3 and EZH2; RNA Pol II ChIP; EZH2 siRNA knockdown\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP combined with RNAi rescue; single lab\",\n      \"pmids\": [\"17911618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FBXO11, a member of the Skp1-Cullin-1-F-box E3 ligase complex, binds CIITA (identified by unbiased proteomics), ubiquitinates CIITA, and regulates CIITA protein half-life through the ubiquitin-proteasome system; FBXO11 deficiency increases MHC class II expression at the promoter, transcript, and surface levels.\",\n      \"method\": \"Unbiased proteomic identification of CIITA-binding proteins; co-immunoprecipitation; cycloheximide chase assay; FBXO11 knockout cells; MHC-II reporter and surface expression assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — unbiased proteomics plus biochemical E3 ligase assay plus KO cells with multiple readouts\",\n      \"pmids\": [\"37279268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NFAT5 is required for CIITA and MHC class II expression specifically in macrophages (not dendritic cells); NFAT5 binds and activates a remote upstream enhancer of the Ciita locus that loops to interact with the myeloid Ciita promoter I, and this enhancer shows NFAT5-dependent H3K27 acetylation.\",\n      \"method\": \"NFAT5-deficient macrophages; ChIP-seq (NFAT5 immunoprecipitation); chromosome conformation capture; histone modification ChIP; in vivo graft rejection assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq, 3C, KO cells, and in vivo functional assay\",\n      \"pmids\": [\"30327417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The RFX complex (including RFX5 and RFXAP) is required for both constitutive and CIITA-induced MHC class I, MHC class II, and beta2-microglobulin transactivation, and the X1 box within the S-X-Y region is the critical cis-element mediating CIITA-dependent transactivation of MHC class I and beta2m promoters.\",\n      \"method\": \"Type III BLS cell lines lacking RFX; promoter mutant reporter assays; complementation with RFX5 and RFXAP expression constructs\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic complementation in BLS patient cells combined with promoter mutant reporters\",\n      \"pmids\": [\"9806639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CIITA in complex with RFX5 mediates IFN-γ-induced repression of collagen type I gene transcription in smooth muscle cells; IFN-γ increases nuclear levels of CIITA isoforms III and IV in SMCs correlating with decreased collagen type I and increased MHC II gene expression.\",\n      \"method\": \"CIITA isoform transfection; nuclear fractionation; COL1A promoter reporter assays; ChIP implied by previous work; RFX5 knockdown by simvastatin treatment\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — transfection and nuclear fractionation; mechanistic basis from prior studies; single lab\",\n      \"pmids\": [\"16439692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CIITA possesses intrinsic acetyltransferase (AT) and kinase activities that contribute to MHC class I and II gene transcription; as a general transcription factor, CIITA functionally replaces the TFIID component TAF1, and its AT and kinase substrate specificities parallel those of TAF1.\",\n      \"method\": \"Review integrating enzymatic activity assays (acetyltransferase and kinase), mutagenesis data, and functional transcription assays from multiple studies\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — summarizes enzymatic data from multiple studies but is a review; enzymatic activities established in primary data\",\n      \"pmids\": [\"24391648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Genome-wide ChIP-seq mapping reveals 843 CIITA binding intervals covering 442 genes (95% outside the MHC), including histone gene clusters; 60% of intervals lack RFX5 binding, indicating CIITA can be recruited independently of the canonical enhanceosome at non-MHC loci; allele-specific NF-κB recruitment mediates trans-regulation by a CIITA intronic variant.\",\n      \"method\": \"ChIP-seq in primary human B cells and monocytes; eQTL mapping; allele-specific ChIP\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq with orthogonal eQTL and allele-specific validation\",\n      \"pmids\": [\"25366989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Genome-wide CIITA ChIP-seq in Raji B cells identifies 480 binding sites predominantly at active promoters/enhancers; CIITA binding at non-regulated loci is associated with increased H3K27 acetylation, suggesting CIITA poises chromatin at these sites; computational modeling identifies XY-box sequence constraints that distinguish CIITA-regulated from merely CIITA-bound sites.\",\n      \"method\": \"ChIP-seq; CRISPR/Cas9-generated CIITA-null cells; RNA-seq in CIITA-null cells; computational sequence modeling\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq plus CRISPR KO with transcriptomic readout and computational validation\",\n      \"pmids\": [\"25753668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CIITA negatively regulates IL-10 expression in dendritic cells; CIITA co-transfection with an IL-10 promoter reporter decreases IL-10 promoter activity, and reintroduction of CIITA into CIITA-/- DCs reduces IL-10 production, establishing a transcriptional repressor function of CIITA beyond MHC class II regulation.\",\n      \"method\": \"CIITA-/- mouse DCs; IL-10 promoter-reporter transfection; CIITA reconstitution; ELISA and RT-PCR\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO plus promoter reporter plus reconstitution; single lab\",\n      \"pmids\": [\"15661876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CIITA, RFX, and CREB interact to form the MHC class II enhanceosome; RFX and CIITA make variable, promoter-dependent contributions to histone acetylation, TBP, TFIIB, and RNA Pol II recruitment across four co-regulated MHC class II family genes.\",\n      \"method\": \"ChIP for histones H3/H4 acetylation, TBP, TFIIB, Pol II in RFX-deficient and CIITA-deficient cells across multiple promoters\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic ChIP across multiple genes in defined mutant cell lines\",\n      \"pmids\": [\"11889043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CREB and phospho-CREB interact directly with both CIITA and the RFX5 subunit through the C-terminal domain of CREB; phosphorylation of CREB enhances MHC class II promoter transcription; phospho-CREB occupancy at the HLA-DRA promoter was detected by ChIP.\",\n      \"method\": \"Co-immunoprecipitation with CREB deletion mutants; reporter assays; ChIP\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — co-IP with domain mapping plus ChIP; single lab\",\n      \"pmids\": [\"16730065\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CIITA is a non-DNA-binding NLR-family transcriptional coactivator that serves as the master regulator of MHC class II (and, secondarily, MHC class I) gene expression: it is expressed from cell-type-specific promoters induced by IFN-γ (via JAK-STAT1-IRF1 and BRG1/SWI/SNF-dependent chromatin remodeling), nucleates an enhanceosome by interacting with the DNA-binding factors RFX5/RFXANK, NF-Y, and CREB at conserved S-X-Y promoter modules, recruits P-TEFb (CDK9/Cyclin T1) and CDK7 to phosphorylate RNA Pol II Ser5 for transcription initiation, coordinates HAT (PCAF/CBP/GCN5) and HDAC activities to control histone acetylation, and is itself post-translationally regulated by acetylation (PCAF/SIRT1), phosphorylation (at Ser286/288/293), arginine methylation (PRMT1-mediated degradation), ubiquitination (enhancing function; FBXO11-mediated proteasomal degradation), and nuclear/cytoplasmic shuttling; beyond antigen presentation, CIITA acts as a viral restriction factor by competing with HIV Tat for P-TEFb and blocking HTLV-1 Tax-1-dependent NF-κB activation, and induces antiviral resistance by activating CD74 p41 to block cathepsin-mediated viral entry.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CIITA is the master transcriptional coactivator of MHC class II genes and a key regulator of MHC class I expression, functioning as a non-DNA-binding NLR-family protein that nucleates an enhanceosome at conserved S-X-Y promoter modules by interacting with the DNA-binding factors RFX5, RFXANK, NF-Y, and CREB [PMID:7749984, PMID:9177217, PMID:11889043]. CIITA is expressed from cell-type-specific promoters whose induction by IFN-γ requires STAT1/IRF1 signaling and BRG1/SWI/SNF-dependent chromatin remodeling at distal enhancers, and it drives transcription initiation by recruiting P-TEFb (CDK9/Cyclin T1) and CDK7 to phosphorylate RNA Pol II Ser5, while coordinating histone acetyltransferases and deacetylases to control promoter acetylation state [PMID:8016643, PMID:11953317, PMID:18500344, PMID:10661406, PMID:14517250]. CIITA activity is regulated post-translationally by acetylation (PCAF/CBP; counteracted by SIRT1), phosphorylation at Ser286/288/293, arginine methylation by PRMT1 promoting degradation, and FBXO11-mediated ubiquitin-proteasomal turnover, all of which modulate its nuclear accumulation and enhanceosome occupancy [PMID:11046145, PMID:21890893, PMID:28094290, PMID:37279268]. Beyond antigen presentation, CIITA acts as a viral restriction factor—competing with HIV Tat for P-TEFb binding, blocking HTLV-1 Tax-1-dependent NF-κB activation, and inducing CD74 p41-dependent resistance to Ebola virus and SARS-CoV-2 entry—and represses non-immune genes including collagen and IL-10 [PMID:10661406, PMID:21813598, PMID:26792751, PMID:32855215, PMID:15247294].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"The identity of the factor controlling MHC class II induction was unknown; transfection of CIITA into class II-negative cells restored MHC-II expression without IFN-γ, establishing CIITA as the master regulator of both constitutive and inducible MHC class II transcription.\",\n      \"evidence\": \"Gain-of-function transfection rescue in class II-negative cells with IFN-γ stimulation assays\",\n      \"pmids\": [\"8016643\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CIITA activates transcription without directly binding DNA was unknown\", \"Whether CIITA controlled MHC class I was not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"How CIITA activates MHC-II promoters without DNA binding was unclear; domain analysis showed CIITA acts as a coactivator that directs activity through the X box element and nucleates a higher-order complex, possessing a potent activation domain but no DNA-binding capacity.\",\n      \"evidence\": \"Transfection with wild-type and mutant CIITA; gel-shift/complex formation assays at X box\",\n      \"pmids\": [\"7749984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the DNA-binding partner(s) that tether CIITA to the promoter was not resolved\", \"Activation domain targets were unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"How CIITA is tethered to promoters and how its expression is diversified across cell types were open questions; RFX5 was identified as the direct DNA-binding partner providing promoter specificity, and three cell-type-specific promoters were mapped, explaining constitutive versus inducible expression patterns.\",\n      \"evidence\": \"Yeast two-hybrid and far-Western for RFX5 interaction; promoter-reporter assays in dendritic cells, B cells, and IFN-γ-treated cells\",\n      \"pmids\": [\"9177217\", \"9184229\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other enhanceosome components (NF-Y, CREB) had not yet been characterized as CIITA partners\", \"How CIITA interfaces with the general transcription machinery was unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Whether CIITA regulated genes beyond MHC class II was untested; CIITA was shown to transactivate MHC class I genes through the site alpha element, broadening its role to the entire antigen presentation pathway.\",\n      \"evidence\": \"Transfection of CIITA into class I-deficient cells; promoter mutant reporters; IFN-γ induction in CIITA-induction-defective G3A cells\",\n      \"pmids\": [\"9175837\", \"9175838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CIITA uses the same enhanceosome at class I versus class II promoters was unclear\", \"RFX requirement for class I activation was not yet demonstrated\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"The requirement for the RFX complex at MHC class I and β2m promoters was uncertain; complementation of RFX-deficient BLS patient cells showed that RFX5/RFXAP and the X1 box are essential for CIITA-dependent transactivation of both MHC-I and MHC-II genes.\",\n      \"evidence\": \"Genetic complementation in type III BLS cells; promoter mutant reporters\",\n      \"pmids\": [\"9806639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the full enhanceosome assembles in ordered steps was not resolved\", \"Whether additional cofactors beyond RFX are needed for class I activation was unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"How CIITA connects to the transcription elongation/initiation machinery was unknown; CIITA was found to bind P-TEFb (Cyclin T1/CDK9) on the same surface used by HIV Tat, and CIITA was simultaneously shown to be acetylated by PCAF/CBP to regulate its nuclear-cytoplasmic shuttling.\",\n      \"evidence\": \"Competition binding assays and RNA-tethered transcription for P-TEFb; in vitro acetylation assays with mutagenesis and subcellular fractionation for acetylation\",\n      \"pmids\": [\"10661406\", \"11046145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether P-TEFb recruitment leads to Pol II CTD phosphorylation at CIITA target promoters was not shown\", \"Kinases responsible for CIITA's own phosphorylation were unidentified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The contribution of the leucine-rich repeat (LRR) domain was undefined; LRR mutations abolished nuclear localization and in vivo promoter recruitment (by ChIP) without disrupting direct RFX5 binding, establishing the LRR as essential for nuclear import and chromatin-level function.\",\n      \"evidence\": \"LRR alanine mutagenesis; ChIP; nuclear localization microscopy; pull-down with enhanceosome components\",\n      \"pmids\": [\"11003667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LRRs sense a ligand analogous to other NLR proteins was not addressed\", \"Structural basis of LRR-mediated nuclear import was not resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Whether CIITA functions as a monomer or oligomer was unknown; CIITA was shown to self-associate through its GTP-binding domain via LXXLL motifs, suggesting oligomerization is integral to its activity.\",\n      \"evidence\": \"Yeast two-hybrid; co-immunoprecipitation; domain-deletion analysis\",\n      \"pmids\": [\"11438649\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry of the oligomer was not determined\", \"Whether GTP binding/hydrolysis regulates oligomerization was untested\", \"Not independently confirmed by a second laboratory\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"How CIITA expression is epigenetically induced at its own locus was unclear; BRG1 was shown to be recruited to the CIITA promoter in an IFN-γ-dependent manner, and its ATPase activity was required for chromatin remodeling permitting CIITA transcription.\",\n      \"evidence\": \"ChIP for BRG1; reconstitution with ATPase-dead K798R mutant; DNase I footprinting and restriction enzyme accessibility\",\n      \"pmids\": [\"11953317\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRG1 acts directly or is recruited by a specific transcription factor at the CIITA locus was not defined\", \"Distal regulatory elements had not been mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The temporal order of cofactor recruitment and the mechanism of transcription initiation at MHC-II promoters were unresolved; CIITA was shown to recruit CDK7 and CDK9, enhancing Ser5 phosphorylation of RNA Pol II to initiate transcription, while ubiquitination of CIITA enhanced enhanceosome association and HDAC1 antagonized it.\",\n      \"evidence\": \"ChIP-based temporal dissection; kinase activity assays; ubiquitination assays; co-IP of HDAC1/mSin3A with CIITA; HAT/HDAC inhibitor experiments\",\n      \"pmids\": [\"14517250\", \"14528304\", \"12697811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The E3 ubiquitin ligase responsible for activating ubiquitination of CIITA was not identified\", \"Whether CIITA ubiquitination is degradative or non-degradative in this context was ambiguous\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Whether CIITA controlled non-MHC target genes was largely unexplored; microarray analysis of CIITA-deficient DCs identified plexin-A1 as a CIITA target whose knockdown impaired T cell stimulation, revealing CIITA's role in DC–T cell communication beyond antigen presentation.\",\n      \"evidence\": \"cDNA microarray in CIITA-deficient vs. control DCs; shRNA knockdown of plexin-A1; T cell stimulation assays\",\n      \"pmids\": [\"12910265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CIITA directly binds the plexin-A1 promoter was not shown\", \"Breadth of non-MHC targets was not systematically assessed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Dual roles of CIITA as both activator and repressor at different loci were emerging; CIITA was found to repress collagen COL1A2 transcription by displacing RNA Pol II from the promoter via RFX5-mediated recruitment, while phosphorylation at Ser286/288/293 was shown to negatively regulate nuclear CIITA activity.\",\n      \"evidence\": \"ChIP and shRNA at COL1A2 promoter; site-directed mutagenesis of serine residues with endogenous MHC-II readout and nuclear fractionation\",\n      \"pmids\": [\"15247294\", \"15210796\", \"11889043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase(s) phosphorylating Ser286/288/293 were not identified\", \"Whether collagen repression occurs in non-smooth-muscle cell contexts was untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Pathogen evasion of CIITA and additional CIITA cofactors were being characterized; M. tuberculosis 19-kDa lipoprotein was found to silence CIITA via TLR2-MAPK-driven histone hypoacetylation at promoter IV, and CREB/phospho-CREB were shown to directly interact with CIITA and RFX5 to enhance enhanceosome function.\",\n      \"evidence\": \"ChIP in TLR2-/- macrophages with MAPK inhibitors; co-IP of CREB deletion mutants with CIITA; phospho-CREB ChIP\",\n      \"pmids\": [\"16547269\", \"16730065\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other pathogens use the same TLR2-MAPK-CIITA silencing axis was unknown\", \"Structural basis of CREB–CIITA interaction was not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"How the CIITA locus is regulated at the three-dimensional chromatin level was unknown; BRG1 was found to be recruited to distal enhancers that loop to the CIITA promoter, establishing a hierarchical model in which BRG1-dependent histone activation marks precede STAT1/IRF1/p300 recruitment.\",\n      \"evidence\": \"ChIP-seq; chromosome conformation capture (3C); BAC deletion analysis of distal elements\",\n      \"pmids\": [\"18500344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional transcription factors cooperate at the distal enhancer was not fully resolved\", \"3D looping dynamics during IFN-γ signaling were not captured in real time\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Post-translational control of CIITA stability and non-immune functions of CIITA were expanding; SIRT1 was identified as a CIITA deacetylase that stabilizes CIITA and promotes MHC-II expression, while CIITA was shown to inhibit myogenesis by binding myogenin and displacing Pol II from muscle gene promoters.\",\n      \"evidence\": \"Co-IP and deacetylation assays for SIRT1–CIITA; ChIP at muscle-specific promoters; CIITA overexpression/knockdown in myoblasts\",\n      \"pmids\": [\"21890893\", \"21576360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SIRT1-CIITA axis operates in professional APCs in vivo was not tested\", \"CIITA's role in muscle physiology under non-inflammatory conditions was not explored\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Whether CIITA had direct antiviral functions beyond MHC upregulation was unknown; CIITA was found to physically interact with HTLV-1 Tax-1 and impair Tax-1 association with PCAF, CREB, and ATF1, thereby blocking HTLV-1 LTR activation.\",\n      \"evidence\": \"Domain-mapping co-IP; luciferase LTR reporter; coactivator overexpression rescue\",\n      \"pmids\": [\"21813598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this restriction operates in primary HTLV-1-infected T cells was not demonstrated\", \"Mechanism by which CIITA displaces coactivators from Tax-1 was not structurally resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The genome-wide binding landscape of CIITA was unknown; ChIP-seq revealed ~800 CIITA binding intervals covering >400 genes, 95% outside the MHC, with 60% lacking RFX5, establishing that CIITA has widespread RFX-independent genomic occupancy and can poise chromatin via H3K27 acetylation.\",\n      \"evidence\": \"ChIP-seq in primary B cells and monocytes; CRISPR/Cas9 CIITA-null cells with RNA-seq; eQTL and allele-specific ChIP\",\n      \"pmids\": [\"25366989\", \"25753668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of CIITA binding at most non-MHC sites was not determined\", \"RFX-independent recruitment mechanism was not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"How CIITA restricts HTLV-1-driven NF-κB signaling was mechanistically unresolved; CIITA was found to act at both cytoplasmic and nuclear levels—retaining Tax-1 in an inactive IκB complex in the cytoplasm and sequestering Tax-1/RelA in nuclear bodies—while PRMT5 was identified as a CIITA-recruited histone arginine methyltransferase that promotes MHC-II activation.\",\n      \"evidence\": \"Subcellular fractionation and nuclear body imaging for Tax-1/NF-κB; co-IP and ChIP with enzyme-dead PRMT5 mutant for MHC-II\",\n      \"pmids\": [\"26792751\", \"26972221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CIITA-mediated NF-κB inhibition affects other NF-κB-dependent viral or cellular programs was not explored\", \"Relative contribution of PRMT5 versus other histone modifiers at MHC-II promoters was not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Macrophage-specific regulation of the CIITA locus was poorly understood; NFAT5 was found to bind and activate a remote upstream enhancer of Ciita that loops to macrophage-specific promoter I, with NFAT5-dependent H3K27 acetylation controlling macrophage MHC-II expression and graft rejection in vivo.\",\n      \"evidence\": \"NFAT5-deficient macrophages; ChIP-seq; 3C; in vivo graft rejection assay\",\n      \"pmids\": [\"30417417\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NFAT5-CIITA axis is relevant in human macrophages was not shown\", \"Signals activating NFAT5 at the CIITA enhancer were not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Whether CIITA could restrict viral entry independently of adaptive immunity was unknown; a genome-wide screen identified CIITA-driven expression of CD74 p41 as a mechanism blocking cathepsin-dependent processing required for Ebola virus and SARS-CoV-2 entry, establishing CIITA as an innate antiviral restriction factor.\",\n      \"evidence\": \"Transposon-mediated gene-activation screen; CIITA/CD74 knockdown and overexpression; viral infection assays with cathepsin inhibitors\",\n      \"pmids\": [\"32855215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD74 p41-mediated restriction operates in primary macrophages or DCs during natural infection was not tested\", \"Breadth of viruses susceptible to this mechanism was not determined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The E3 ligase controlling CIITA proteasomal turnover was unidentified; FBXO11 was discovered by unbiased proteomics as an SCF-type E3 ligase that ubiquitinates CIITA and determines its protein half-life, with FBXO11 deficiency increasing MHC-II expression at transcript, promoter, and surface levels.\",\n      \"evidence\": \"Unbiased proteomic identification; co-IP; cycloheximide chase; FBXO11 knockout cells; MHC-II reporter and surface expression\",\n      \"pmids\": [\"37279268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific lysine residues on CIITA targeted by FBXO11 were not mapped\", \"Whether FBXO11 and the previously described activating ubiquitination represent distinct ubiquitin chain types was not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of enhanceosome assembly, whether GTP binding/hydrolysis by the NLR-type domain regulates CIITA activity, the functional impact of CIITA at the majority of its genome-wide binding sites outside the MHC, and the in vivo significance of CIITA's antiviral restriction functions during natural infection.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of CIITA or its enhanceosome exists\", \"GTPase activity and potential ligand sensing by the NLR domain are functionally uncharacterized\", \"Biological significance of RFX-independent genome-wide CIITA binding remains undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 3, 4, 5, 12, 13, 35]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [17, 18, 19]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 7, 14, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 3, 5, 12, 35]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 4, 19, 29]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [9, 11, 21, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [17, 18, 19, 20]}\n    ],\n    \"complexes\": [\n      \"MHC-II enhanceosome (RFX5/RFXANK/NF-Y/CREB/CIITA)\"\n    ],\n    \"partners\": [\n      \"RFX5\",\n      \"RFXANK\",\n      \"CDK9\",\n      \"CCNT1\",\n      \"PCAF\",\n      \"HDAC1\",\n      \"SIRT1\",\n      \"FBXO11\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}